Cleo Diagnostics Reports Success in Ovarian Cancer Test
A new proof-of-concept study demonstrates high sensitivity and specificity for early detection of ovarian cancer.
Updated on Oct. 21, 2026 in Cancer
Live Poll
Would you trust a new cancer screening test that has only completed initial proof-of-concept studies?
Cleo Diagnostics has announced positive results from a proof-of-concept study for a new ovarian cancer screening test. The test achieved high marks for sensitivity and specificity across both high-risk and general population screening groups.
Why it matters
The company aimed to demonstrate that the underlying biology and panel design of the screening test are sound. These findings represent a significant step toward developing reliable diagnostic tools for early-stage ovarian cancer detection.
The study of 247 participants showed an area under the curve of 0.99 for Stage I cancers and 0.98 for all-stage cancers. High-risk screening achieved 98.7% specificity, while general population screening reached 100% specificity.
The players
Cleo Diagnostics
This biotechnology company focuses on the development of innovative diagnostic screening tests for cancer detection.
National Cancer Institute
This is a federal agency within the United States that coordinates national research efforts against cancer.
The details
Researchers evaluated samples from the UK Collaborative Trial of Ovarian Cancer Screening and a large-scale trial sponsored by the US National Cancer Institute. The cohort included 87 healthy individuals, 67 women with benign disease, and 93 with ovarian cancer, including 62 Stage I cases.
Timeline
The study results were officially published on October 21, 2026.
A regulatory submission for a pre-surgical test is planned for 2027.
The Big Picture
This study leverages samples from the UK Collaborative Trial of Ovarian Cancer Screening to validate new diagnostic capabilities. This effort builds upon historical research efforts by utilizing established trial data to refine early-detection technologies.
Successful development of this test could eventually provide patients with more accurate screening options for early-stage ovarian cancer. This may lead to improved clinical outcomes through earlier medical intervention.
The takeaway
Early detection remains a critical factor in treating ovarian cancer effectively. This study highlights how new diagnostic panels can improve accuracy rates for high-risk populations.
What happens next
Cleo Diagnostics intends to conduct next-stage testing on a larger independent cohort to confirm current performance estimates. The company is also preparing a regulatory submission for its pre-surgical ovarian cancer test in the United States in 2027.
Further reading
For more information on the latest research and diagnostic tools, visit the Cancer section.
Source note: This article includes information reported by Small Caps.
Live Poll
Would you trust a new cancer screening test that has only completed initial proof-of-concept studies?
